Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB) Change in Receivables (2024 - 2025)

Nuvation Bio (NUVB) has disclosed Change in Receivables for 2 consecutive years, with $7.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Receivables fell 38.52% to $7.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.4 million, a 73.64% decrease, with the full-year FY2025 number at $3.4 million, down 73.64% from a year prior.
  • Change in Receivables was $7.8 million for Q4 2025 at Nuvation Bio, up from $5.6 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $12.6 million in Q4 2024 to a low of -$12.3 million in Q1 2025.